Amphastar Reports Q1 2026 Earnings with Mixed Performance Across Product Lines
Amphastar (AMPH) reported net revenue of $171.2 million for the first quarter of 2026, slightly up from the prior-year period due to new product launches and stable base business performance. However, Vaxini sales declined by 15% despite increased unit volume, while Glucagon Injection Sales dropped sharply by 56%. Gross margin improved significantly to 71%, driven primarily by higher revenue.
Tickers: $AMPH
Topics: gross_margin product_sales revenue